Advances in Delivery Vectors for Gene Therapy in Liver Cancer

References

• Kunst C , HadererM , HeckelS , SchlosserS , MüllerM. The p53 family in hepatocellular carcinoma. Transl. Cancer Res.5(6), 632–638 (2016).
   Web of Science ®Google Scholar
• Institute NC . Cancer stat facts: Liver and intrahepatic bile duct cancer (2019). https://seer.cancer.gov/statfacts/html/livibd.html
   Google Scholar
• Waghray A , MuraliAR , MenonKVN. Hepatocellular carcinoma: From diagnosis to treatment. World J. Hepatol.7(8), 1020–1029 (2015).
   PubMedGoogle Scholar
• Ghassan K. Abou-Alfa WJ , MaeveLowery , MichaelD'Angelicaet al. Liver and bile duct cancer. In: Abeloff's Clinical Oncology.NiederhuberJ ( Ed.). 1373–1396 (2014).
   Google Scholar
• Valverde-López F , AngelesLópez Garrido M , Ortega-SuazoEJ , Vadillo-CallesF , Muffak-GraneroK , Nogueras-LópezF. Results of 15-Year experience in liver transplant for hepatocellular carcinoma. Transplant Proc.50(2), 617–618 (2018).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RicciS , MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cazejust J , BessoudB , ColignonN , Garcia-AlbaC , PlanchéO , MenuY. Hepatocellular carcinoma vascularization: from the most common to the lesser known arteries. Diagn. Interv. Imaging95(1), 27–36 (2014).
   PubMed Web of Science ®Google Scholar
• Lam FDaMGEH . Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res.33, 4711–4718 (2013).
   PubMed Web of Science ®Google Scholar
• Chen S CJ , XiWet al. Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma. Am. J. Clin. Oncol. Rep.37 (2014).
   Google Scholar
• Tian G , LiuJ , ZhouJS , ChenW. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot Phase II trial. Anticancer Drug.20(5), 389–395 (2009).
   Google Scholar
• Ou SQ , MYL , KangP , LiZK , MengZB , FQ. Recombinant adenovirus-p53 gene therapy combined with transcatheter arterial chemoembolization for p53-positive and p53-negative hepatocellular carcinoma. Chin. J. Interv. Imaging Ther.7, 354–357 (2010).
   Google Scholar
• Guan Y-S , LiuY , HeQet al. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up. World J. Gastroenterol.17(16), 2143–2149 (2011).
   PubMed Web of Science ®Google Scholar
• Yang Z , WangD , WangGet al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.136(4), 625–630 (2010).
   PubMed Web of Science ®Google Scholar
• Kim KI , ChungHK , ParkJH , LeeYJ , KangJH. Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma. World J. Gastroenterol.22(27), 6127–6134 (2016).
   PubMed Web of Science ®Google Scholar
• Yoon AR , HongJ , KimM , YunC-O. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. Sci. Rep.8(1), 2233 (2018).
   PubMedGoogle Scholar
• Peng Y-F , ShiY-H , DingZ-Bet al. Alpha-fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. PLoS One8(2), e53072 (2013).
   PubMed Web of Science ®Google Scholar
• Kim KI , ChungHK , ParkJH , LeeYJ , KangJH. Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma. World J. Gastroenterol.22(27), 6127–6134 (2016).
   PubMed Web of Science ®Google Scholar
• Mao CY , HuaHJ , ChenP , YuDC , CaoJ , TengLS. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int.8(3), 282–287 (2009).
   PubMed Web of Science ®Google Scholar
• Dhungel B , AndrzejewskiS , JayachandranAet al. Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma. Gene Ther.25(2), 115–128 (2018).
   PubMed Web of Science ®Google Scholar
• Jiang H , GuoS , XiaoDet al. Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency. Oncotarget8(23), 37694–37704 (2017).
   PubMedGoogle Scholar
• Hu H , QiuY , GuoMet al. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models. Oncotarget6(2), 1079–1089 (2014).
   Google Scholar
• Zhou G , LatchoumaninO , HebbardLet al. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv. Drug Deliv. Rev.134, 107–121 (2018).
   PubMed Web of Science ®Google Scholar
• Wang CY , LinBL , ChenCH. An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers. Int. J. Cancer.138(4), 918–926 (2016).
   PubMed Web of Science ®Google Scholar
• Chen F , ZhangF , LiuY , CaiC. Simply and sensitively simultaneous detection hepatocellular carcinoma markers AFP and miRNA-122 by a label-free resonance light scattering sensor. Talanta.186, 473–480 (2018).
   PubMed Web of Science ®Google Scholar
• Cho Y , LeeYB , LeeJHet al. Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS One11(8), e0160822 (2016).
   PubMed Web of Science ®Google Scholar
• Babaei M , AbnousK , TaghdisiSMet al. Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma. Nanomedicine12(11), 1261–1279 (2017).
   PubMed Web of Science ®Google Scholar
• Xiao S , LiuZ , DengRet al. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo. J. Control. Rel.258, 130–145 (2017).
   PubMed Web of Science ®Google Scholar
• Jiang J , ChenH , YuCet al. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.(epidermal growth factor receptors and poly(lactic-co-glycolic acid))(Report). Nanomedicine10(12), 1863 (2015).
   PubMed Web of Science ®Google Scholar
• Baruteau J , WaddingtonSN , AlexanderIE , GissenP. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J. Inherit. Metab. Dis.40(4), 497–517 (2017).
   PubMed Web of Science ®Google Scholar
• Lundstrom K . Viral Vectors in gene therapy. Diseases (Basel, Switzerland)6(2), 42 (2018).
   PubMedGoogle Scholar
• Jacobs F , GordtsSC , MuthuramuI , DeGeest B. The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives. Pharmaceuticals (Basel)5(12), 1372–1392 (2012).
   PubMedGoogle Scholar
• Braet F , WisseE. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp. Hepatol.1(1), 1 (2002).
   PubMedGoogle Scholar
• Snoeys J , LievensJ , WisseEet al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther.14(7), 604–612 (2007).
   PubMed Web of Science ®Google Scholar
• Szilagyi JF , BerrimanJ. Herpes simplex virus L particles contain spherical membrane-enclosed inclusion vesicles. J. Gen. Virol.75(Pt 7), 1749–1753 (1994).
   PubMedGoogle Scholar
• Banerjee R . Liposomes: applications in medicine. J. Biomater. Appl.16(1), 3–21 (2001).
   PubMed Web of Science ®Google Scholar
• Chen H . Comparative observation of the recombinant adeno-associated virus 2 using transmission electron microscopy and atomic force microscopy. Microsc. Microanal.13(5), 384–389 (2007).
   PubMed Web of Science ®Google Scholar
• Tao N , GaoGP , ParrMet al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther.3(1), 28–35 (2001).
   PubMed Web of Science ®Google Scholar
• Merlin S , CannizzoES , BorroniEet al. A novel platform for immune tolerance induction in hemophilia A mice. Mol. Ther.25(8), 1815–1830 (2017).
   PubMed Web of Science ®Google Scholar
• Fu X , RiveraA , TaoL , DeGeest B , ZhangX. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol. Ther.20(2), 339–346 (2012).
   PubMed Web of Science ®Google Scholar
• Lin Y , ZhangH , LiangJet al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl Acad. Sci. USA111(42), E4504–E4512 (2014).
   PubMed Web of Science ®Google Scholar
• Ke P-Y . The multifaceted roles of autophagy in flavivirus–host interactions. Int. J. Mol. Sci.19(12), 3940 (2018).
   PubMed Web of Science ®Google Scholar
• Chen A , ZhangY , MengGet al. Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment. Sci. Rep.7(1), 5170–5170 (2017).
   PubMedGoogle Scholar
• Ong H-T , FederspielMJ , GuoCMet al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatol.59(5), 999–1006 (2013).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V , van GoolS , StueckerW. Breaking therapy resistance: an update on oncolytic Newcastle disease virus for improvements of cancer therapy. Biomedicines7(3), 66 (2019).
   PubMed Web of Science ®Google Scholar
• Wei D , LiQ , WangX-Let al. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. J. Exp. Clin. Cancer Res.34, 153–153 (2015).
   PubMed Web of Science ®Google Scholar
• Altomonte J , MarozinS , SchmidRM , EbertO. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther.18(2), 275–284 (2010).
   PubMed Web of Science ®Google Scholar
• McCarthy C , JayawardenaN , BurgaLN , BostinaM. Developing picornaviruses for cancer therapy. Cancers (Basel)11(5), 685 (2019).
   PubMed Web of Science ®Google Scholar
• Lundstrom K . Viral vector-based cancer immunotherapy. Austin Immunol.1(2), 1008 (2016).
   Google Scholar
• Rosewell A , VetriniF , NgP. Helper-dependent adenoviral vectors. J. Genet. Syndr. Gene Ther. (Suppl. 5), 001 (2011).
   PubMedGoogle Scholar
• Lee CS , BishopES , ZhangRet al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis.4(2), 43–63 (2017).
   PubMed Web of Science ®Google Scholar
• Gregory SM , NazirSA , MetcalfJP. Implications of the innate immune response to adenovirus and adenoviral vectors. Future Virol.6(3), 357–374 (2011).
   PubMed Web of Science ®Google Scholar
• Raper SE , YudkoffM , ChirmuleNet al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther.13(1), 163–175 (2002).
   PubMed Web of Science ®Google Scholar
• Raper SE , ChirmuleN , LeeFSet al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab.80(1-2), 148–158 (2003).
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N , NgT , IannittiDet al. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum. Gene Ther.24(8), 761–765 (2013).
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N , PalmerDJ , BeaudetAl , CareyKD , FinegoldM , NgP. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther.15(1), 35–46 (2004).
   PubMed Web of Science ®Google Scholar
• Kim J et al. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials32(22), 5158–5166 (2011).
   PubMed Web of Science ®Google Scholar
• Leggiero E , AstoneD , CerulloVet al. PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice. Gene Ther.20(12), 1124–1130 (2013).
   PubMed Web of Science ®Google Scholar
• Choi JW , KimHA , NamK , NaY , YunCO , KimS. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy. J. Control. Rel.220(Pt B), 691–703 (2015).
   PubMedGoogle Scholar
• Huang P , KakuH , ChenJet al. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. Cancer Gene Ther.17(7), 484–491 (2010).
   PubMed Web of Science ®Google Scholar
• Kishimoto H , UrataY , TanakaN , FujiwaraT , HoffmanRM. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol. Cancer Ther.8(11), 3001–3008 (2009).
   PubMed Web of Science ®Google Scholar
• Lin WH , YehSH , YangWJet al. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int. J. Cancer.132(6), 1451–1462 (2013).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT02293850 , Phase I study to evaluate the safety and efficacy of telomelysin (OBP-301) in patients with hepatocellular carcinoma (2014). https://clinicaltrials.gov/ct2/show/NCT02293850
   Google Scholar
• Sangro B , MazzoliniG , RuizMet al. A Phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther.17, 837 (2010).
   PubMed Web of Science ®Google Scholar
• Kim YH , KimKT , LeeSJet al. Image-aided suicide gene therapy utilizing multifunctional hTERT-targeting adenovirus for clinical translation in hepatocellular carcinoma. Theranostics.6(3), 357–368 (2016).
   PubMed Web of Science ®Google Scholar
• Park JH , KimKI , LeeKCet al. Assessment of alpha-fetoprotein targeted HSV1-tk expression in hepatocellular carcinoma with in vivo imaging. Cancer Biother. Radiopharm.30(1), 8–15 (2015).
   PubMed Web of Science ®Google Scholar
• Chen Z-H , YuYP , ZuoZ-Het al. Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene. Nat. Biotechnol.35, 543 (2017).
   PubMed Web of Science ®Google Scholar
• El-Shemi AG , AshshiAM , NaYet al. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J. Exp. Clin. Can. Res.35, 74–74 (2016).
   PubMed Web of Science ®Google Scholar
• Galal El-Shemi A , MohammedAshshi A , OhEet al. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. Gene Ther.25(1), 54–65 (2018).
   PubMed Web of Science ®Google Scholar
• Curiel DT . The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res.6(9), 3395 (2000).
   PubMed Web of Science ®Google Scholar
• Hallenbeck PL , ChangY-N , HayCet al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther.10(10), 1721–1733 (1999).
   PubMed Web of Science ®Google Scholar
• Brand K , LöserP , ArnoldW , BartelsT , StraussM. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther.5(10), 1363–1371 (1998).
   PubMed Web of Science ®Google Scholar
• O'Shea CC , SoriaC , BagusB , McCormickF. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell.8(1), 61–74 (2005).
   PubMed Web of Science ®Google Scholar
• Heise C , Sampson-JohannesA , WilliamsA , McCormickF , Von HoffDD , KirnDH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med.3(6), 639–645 (1997).
   PubMed Web of Science ®Google Scholar
• Parato KA , SengerD , ForsythPAJ , BellJC. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer.5(12), 965–976 (2005).
   PubMed Web of Science ®Google Scholar
• Makower D , RozenblitA , KaufmanHet al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res.9(2), 693 (2003).
   PubMed Web of Science ®Google Scholar
• Xia Z-J , ChangJ-H , ZhangLet al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Chin. J. Cancer23, 1666–1670 (2004).
   Google Scholar
• Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst.98(5), 298–300 (2006).
   PubMedGoogle Scholar
• Andtbacka RHI , KaufmanHL , CollichioFet al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol.33(25), 2780–2788 (2015).
   PubMed Web of Science ®Google Scholar
• Uch R , GerolamiR , FaivreJet al. Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther.10(9), 689–695 (2003).
   PubMed Web of Science ®Google Scholar
• Seo E , KimS , JhoEH. Induction of cancer cell-specific death via MMP2 promoterdependent Bax expression. BMB Rep.42(4), 217–222 (2009).
   PubMed Web of Science ®Google Scholar
• Cantore A , RanzaniM , BartholomaeCCet al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci. Transl. Med.7(277), 277ra228 (2015).
   Web of Science ®Google Scholar
• Cantore A , MilaniM , AnnoniAet al. Liver-directed gene therapy for hemophilia B with immune stealth lentiviral vectors. Blood.130(Suppl 1), 605–605 (2017).
   Google Scholar
• Levine BL , MiskinJ , WonnacottK , KeirC. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev.4, 92–101 (2017).
   PubMed Web of Science ®Google Scholar
• Guo X , JiangH , ShiBet al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front. Pharmacol.9, 1118–1118 (2018).
   PubMed Web of Science ®Google Scholar
• Milone MC , O'DohertyU. Clinical use of lentiviral vectors. Leukemia32(7), 1529–1541 (2018).
   PubMed Web of Science ®Google Scholar
• Kattenhorn LM , TipperCH , StoicaLet al. Adeno-associated virus gene therapy for liver disease. Hum. Gene Ther.27(12), 947–961 (2016).
   PubMed Web of Science ®Google Scholar
• Nienhuis AW , NathwaniAC , DavidoffAM. Gene therapy for hemophilia. Hum. Gene Ther.27(4), 305–308 (2016).
   PubMed Web of Science ®Google Scholar
• Colella P , RonzittiG , MingozziF. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev.8, 87–104 (2018).
   PubMed Web of Science ®Google Scholar
• Medicine JoG . Gene Therapy Clinical Trials Worldwide (2017). www.abedia.com/wiley/
   Google Scholar
• Chandler RJ , SandsMS , VendittiCP. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models. Hum. Gene Ther.28(4), 314–322 (2017).
   PubMed Web of Science ®Google Scholar
• Srivastava A . In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol.21, 75–80 (2016).
   PubMed Web of Science ®Google Scholar
• Hurlbut GD , ZieglerRJ , NietupskiJBet al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther.18(11), 1983–1994 (2010).
   PubMed Web of Science ®Google Scholar
• Li C , NarkbunnamN , SamulskiRJet al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther.19(3), 288–294 (2012).
   PubMed Web of Science ®Google Scholar
• Chirmule N , XiaoW , TrunehAet al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol.74(5), 2420–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Sun J , ShaoW , ChenXet al. An observational study from long-term AAV re-administration in two hemophilia dogs. Mol. Ther. Methods Clin. Dev.10, 257–267 (2018).
   PubMed Web of Science ®Google Scholar
• Majowicz A , SalasD , ZabaletaNet al. Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5(ch) and AAV1. Mol. Ther.25(8), 1831–1842 (2017).
   PubMed Web of Science ®Google Scholar
• Salas D , KwikkersKL , ZabaletaNet al. Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv.3(17), 2632–2641 (2019).
   PubMed Web of Science ®Google Scholar
• Buning H , SrivastavaA. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol. Ther. Methods Clin. Dev.12, 248–265 (2019).
   PubMed Web of Science ®Google Scholar
• Sayroo R , NolascoD , YinZet al. Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther.23(1), 18–25 (2016).
   PubMed Web of Science ®Google Scholar
• Horner M , KaufmannB , CotugnoGet al. A chemical switch for controlling viral infectivity. Chem. Commun. (Camb).50(71), 10319–10322 (2014).
   PubMed Web of Science ®Google Scholar
• Markusic DM , HerzogRW , AslanidiGVet al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther.18(12), 2048–2056 (2010).
   PubMed Web of Science ®Google Scholar
• Wang L , MorizonoH , LinJet al. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol. Genet. Metab.105(2), 203–211 (2012).
   PubMed Web of Science ®Google Scholar
• Lisowski L , DaneAP , ChuKet al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature.506(7488), 382–386 (2014).
   PubMed Web of Science ®Google Scholar
• Paulk NK , PekrunK , ZhuEet al. Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity. Mol. Ther.26(1), 289–303 (2018).
   PubMed Web of Science ®Google Scholar
• Glushakova LG , LisankieMJ , EruslanovEBet al. AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab.98(3), 289–299 (2009).
   PubMed Web of Science ®Google Scholar
• Ma S , SunJ , GuoYet al. Combination of AAV-TRAIL with miR-221-Zip therapeutic strategy overcomes the resistance to TRAIL induced apoptosis in liver cancer. Theranostics7(13), 3228–3242 (2017).
   PubMed Web of Science ®Google Scholar
• Yuan L , ZhaoH , ZhangL , LiuX. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biol.34(5), 3027–3034 (2013).
   PubMedGoogle Scholar
• Breitbach CJ , BellJC , HwangT-H , KirnDH , BurkeJ. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncol. Virother.4, 25–31 (2015).
   PubMed Web of Science ®Google Scholar
• Chan WM , McFaddenG. Oncolytic Poxviruses. Annu. Rev. Virol.1(1), 119–141 (2014).
   PubMed Web of Science ®Google Scholar
• Cho E , RyuEJ , JiangFet al. Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus. Drug Des. Devel. Ther.12, 2467–2474 (2018).
   PubMed Web of Science ®Google Scholar
• Sae-im J . SillaJen remains confident about Pexa-Vec's value, despite trial failure. Korea Biomed. Rev. (2019).
   Google Scholar
• Lundstrom K . Self-replicating RNA viral vectors in vaccine development and gene therapy. Future Virol.11(5), 345–356 (2016).
   Web of Science ®Google Scholar
• Lundstrom K . Self-Replicating RNA viruses for RNA therapeutics. Molecules (Basel).23(12) (2018).
   PubMed Web of Science ®Google Scholar
• Lai WF , WongWT. Design of polymeric gene carriers for effective intracellular delivery. Trends Biotechnol.36(7), 713–728 (2018).
   PubMed Web of Science ®Google Scholar
• Varshosaz J , FarzanM. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J. Gastroenterol.21(42), 12022–12041 (2015).
   PubMed Web of Science ®Google Scholar
• Durymanov M , ReinekeJ. Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers. Front. Pharmacol.9, 971–971 (2018).
   PubMed Web of Science ®Google Scholar
• Zamboni CG , KozielskiKL , VaughanHJet al. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J. Control. Rel.263, 18–28 (2017).
   PubMed Web of Science ®Google Scholar
• Liu CH , ChernGJ , HsuFFet al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology67(3), 899–913 (2018).
   PubMed Web of Science ®Google Scholar
• El Sharkawi FZ , EwaisSM , FahmyRH , RashedLA. PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma. J. Drug Target.25(6), 513–522 (2017).
   PubMed Web of Science ®Google Scholar
• Yang E , LiX , JinN. The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment. Cancer Cell Int.16, 80–80 (2016).
   PubMed Web of Science ®Google Scholar
• Hu BG , LiuLP , ChenGGet al. Therapeutic efficacy of improved alpha-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma. Exp. Cell Res.324(2), 183–191 (2014).
   PubMed Web of Science ®Google Scholar
• Misra SK , RayT , OstadhosseinF , KimB , RayPS , PanD. Carotenoid nanovector for efficient therapeutic gene knockdown of transcription factor FOXC1 in liver cancer. Bioconjug. Chem.27(3), 594–603 (2016).
   PubMed Web of Science ®Google Scholar
• Fitamant J , KottakisF , BenhamoucheSet al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep.10(10), 1692–1707 (2015).
   PubMed Web of Science ®Google Scholar
• Chen R , XuX , TaoY , QianZ , YuY. Exosomes in hepatocellular carcinoma: a new horizon. J. Cell. Commun. Signal.17(1), 1–1 (2019).
   Google Scholar
• Abudoureyimu M , ZhouH , ZhiYet al. Recent progress in the emerging role of exosome in hepatocellular carcinoma. Cell. Prolif.52(2), e12541 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang Y , LiL , YuJet al. Microvesicle-mediated delivery of transforming growth factor beta1 siRNA for the suppression of tumor growth in mice. Biomaterials35(14), 4390–4400 (2014).
   PubMed Web of Science ®Google Scholar
• Yang N , LiS , LiGet al. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget8(2), 3683–3695 (2016).
   Google Scholar
• Mathiyalagan P , SahooS. Exosomes-based gene therapy for microRNA delivery. Methods Mol. Biol.1521, 139–152 (2017).
   PubMedGoogle Scholar
• Santangelo L , BattistelliC , MontaldoC , CitarellaF , StrippoliR , CicchiniC. Functional roles and therapeutic applications of exosomes in hepatocellular carcinoma. Biomed. Res. Int.2017, 2931813–2931813 (2017).
   PubMed Web of Science ®Google Scholar
• Tai Y-L , ChenK-C , HsiehJ-T , ShenT-L. Exosomes in cancer development and clinical applications. Cancer Sci.109(8), 2364–2374 (2018).
   PubMed Web of Science ®Google Scholar
• Lou G , SongX , YangFet al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol.8, 122–122 (2015).
   PubMed Web of Science ®Google Scholar
• Liang G , KanS , ZhuY , FengS , FengW , GaoS. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int. J. Nanomedicine13, 585–599 (2018).
   PubMed Web of Science ®Google Scholar
• Liang G , KanS , ZhuY , FengS , FengW , GaoS. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. Int. J. of Nanomedicine13, 585–599 (2018).
   PubMed Web of Science ®Google Scholar
• Wang J , LiW , LuZet al. The use of RGD-engineered exosomes for enhanced targeting ability and synergistic therapy toward angiogenesis. Nanoscale9(40), 15598–15605 (2017).
   PubMed Web of Science ®Google Scholar
• Saga K , KanedaY. Virosome presents multimodel cancer therapy without viral replication. Biomed. Res. Int.2013, 764706–764706 (2013).
   PubMed Web of Science ®Google Scholar
• Zakaria MK , KhanI , ManiP , ChattopadhyayP , SarkarDP , SinhaS. Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells. BMC Cancer14, 582 (2014).
   PubMed Web of Science ®Google Scholar
• Carroll D , BeumerKJ. Genome engineering with TALENs and ZFNs: repair pathways and donor design. Methods69(2), 137–141 (2014).
   PubMed Web of Science ®Google Scholar
• Ho BX , LohSJH , ChanWK , SohBS. In vivo genome editing as a therapeutic approach. Int. J. Mol. Sci.19(9), 2721 (2018).
   PubMed Web of Science ®Google Scholar
• Cong L , RanFA , CoxDet al. Multiplex genome engineering using CRISPR/Cas systems. Science.339(6121), 819 (2013).
   PubMed Web of Science ®Google Scholar
• Joung JK , SanderJD. TALE Ns: a widely applicable technology for targeted genome editin. Nat. Rev. Mol. Cell. Biol.14(1), 49–55 (2013).
   PubMed Web of Science ®Google Scholar
• Doudna JA , CharpentierE. The new frontier of genome engineering with CRISPR-Cas9. Science346(6213), 1258096 (2014).
   PubMed Web of Science ®Google Scholar
• Lieber MR . The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem.79, 181–211 (2010).
   PubMed Web of Science ®Google Scholar
• Jasin M , RothsteinR. Repair of strand breaks by homologous recombination. CSH Perspect. Biol.5(11), a012740–a012740).
   Google Scholar
• Helleday T , LoJ , van GentDC , EngelwardBP. DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair6(7), 923–935 (2007).
   PubMed Web of Science ®Google Scholar
• Dominguez AA , LimWA , QiLS. Beyond editing: repurposing CRISPR–Cas9 for precision genome regulation and interrogation. Nat. Rev. Mol. Cell. Biol.17, 5 (2015).
   PubMed Web of Science ®Google Scholar
• Ran FA , HsuPD , LinC-Yet al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell154(6), 1380–1389 (2013).
   PubMed Web of Science ®Google Scholar
• White MK , KhaliliK. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget7(11), 12305–12317 (2016).
   PubMedGoogle Scholar
• Gebler C , LohoffT , Paszkowski-RogaczMet al. Inactivation of cancer mutations utilizing CRISPR/Cas9. J. Natl Cancer. Inst.109(1), djw183 (2016).
   PubMedGoogle Scholar
• Raghunath A , SundarrajK , ArfusoF , SethiG , PerumalE. Dysregulation of Nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance. Cancers10(12), 481 (2018).
   PubMed Web of Science ®Google Scholar
• Lohitesh K , ChowdhuryR , MukherjeeS. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int.18, 44–44 (2018).
   PubMed Web of Science ®Google Scholar
• Bialk P , WangY , BanasK , KmiecEB. Functional gene knockout of NRF2 increases chemosensitivity of human lung cancer A549 cells in vitro and in a xenograft mouse model. Mol. Ther. Oncolytics11, 75–89 (2018).
   PubMed Web of Science ®Google Scholar
• Zhao H , EguchiS , AlamA , MaD. The role of nuclear factor-erythroid 2 related factor 2 (Nrf-2) in the protection against lung injury. Am. J. Physiol. Lung Cell Mol. Physiol.312(2), L155–L162 (2016).
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Liver Cancer C . The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol.3(12), 1683–1691 (2017).
   PubMed Web of Science ®Google Scholar
• Schinzari V , BarnabaV , PiconeseS. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin. Microbiol. Infect.21(11), 969–974 (2015).
   PubMed Web of Science ®Google Scholar
• Sung W-K , ZhengH , LiSet al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet.44, 765 (2012).
   PubMed Web of Science ®Google Scholar
• Scott T , MoyoB , NicholsonSet al. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci. Rep.7(1), 7401 (2017).
   PubMedGoogle Scholar
• Schiwon M , Ehrke-SchulzE , OswaldAet al. One-vector system for multiplexed CRISPR/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors. Mol. Ther. Nucleic. Acids.12, 242–253 (2018).
   PubMedGoogle Scholar
• He Z-Y , ZhangY-G , YangY-Het al. In vivo ovarian cancer gene therapy using CRISPR-Cas9. Hum. Gene Ther.29(2), 223–233 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiY , MaYet al. Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. J. Exp. Clin. Cancer Res.37(1), 216–216 (2018).
   PubMedGoogle Scholar
• Wang X , WuB , ZhongZ. Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells. Oncol. Lett.16(1), 585–593 (2018).
   PubMed Web of Science ®Google Scholar
• Han J , XieC , PeiTet al. Deregulated AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma carcinogenesis and metastasis. Cell Death Dis.8(4), e2736–e2736 (2017).
   PubMedGoogle Scholar
• Qu W , WenX , SuK , GouW. MiR-552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression. J. Cell. Mol. Med.23(2), 1541–1552 (2019).
   PubMed Web of Science ®Google Scholar
• Bowman KR , KimJH , LimCS. Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. J. Ovarian Res.12(1), 38 (2019).
   PubMedGoogle Scholar
• Lu P , ReddBowman KE , BrownSMet al. p53-Bad: a novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy. Mol. Pharm.16(8), 3386–3398 (2019).
   PubMedGoogle Scholar